免疫生物学杂志

Novel and Effective Treatment for Patients with COVID-19 in Stages I to IIIA of the Infection

Abstract

Ronald Palacios Castrillo*

We report here a novel treatment for patients with Covid-19, stages I to IIIA of infection. The combination of Nitazoxanide, Hydroxicloroquine and Zinc effectively eliminated the SARSCov2 virus after 10 days of treatment in 165 of the 172 patients studied, as determined by RT-PCR and antigen in nasal swabs. This triplet of medicines along with Deflazacort and Ribaroxaban successfully treated patients in stages IIB to IIIA of the infection .The treatment described here is readily available, inexpensive and should prove useful to control dissemination and spread of the virus by symptomatic and asymptomatic persons as well as to decrease the mortality.